Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: A functional role for receptor-receptor interaction in vivo

Circulation

Volumn 108, Issue 13, 2003, Pages 1611-1618

  Barki Harrington, Liza ^b   Luttrell, Louis M ^b   Rockman, Howard A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Angiotensin; Heart failure; Pharmacology; Receptors, adrenergic, beta; Signal transduction

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; PROPRANOLOL; VALSARTAN;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEART FAILURE; HEART MUSCLE CELL; HEART RATE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANIMALS; BINDING, COMPETITIVE; CELL LINE; CELLS, CULTURED; COS CELLS; FEMALE; HEART RATE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; ISOPROTERENOL; MACROMOLECULAR SUBSTANCES; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PROPRANOLOL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; TETRAZOLES; VALINE;

EID: 0141841603     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000092166.30360.78     Document Type: Article

References (27)

1. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L-40L.
2. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206-212.
3. 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454-463.
4. Neumann J, Schmitz W, Scholz H, et al. Increase in myocardial Gi-proteins in heart failure. Lancet. 1988;2:936-937.
5. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998;352(suppl I):8-14.
6. Rios CD, Jordan BA, Gomes I, et al. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther. 2001;92: 71-87.
7. Rockman HA, Choi DJ, Akhter SA, et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem. 1998;273:18180-18184.
8. Barki-Harrington L, Bookout AL, Wang G, et al. Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Biochem J. 2003;371: 581-587.
9. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
10. s signaling: targeting the receptor-G protein interface using a peptide minigene encoding the Galpha(s) carboxyl terminus. J Biol Chem. 2002;277:28631-28640.
11. Naga Prasad SV, Barak LS, Rapacciuolo A, et al. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1: a role in receptor sequestration. J Biol Chem. 2001;276:18953-18959.
12. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001; 103:904-912.
13. Sullivan R, Chateauneuf A, Coulombe N, et al. Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors with truncated receptors and metabotropic glutamate receptor 4 supports the GABA(B) heterodimer as the functional receptor. J Pharmacol Exp Ther. 2002;293: 460-467.
14. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 1999;399:697-700.
15. Jordan BA, Trapaidze N, Gomes I, et al. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci U S A. 2001;98:343-348.
16. Oakley RH, Laporte SA, Holt JA, et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem. 2000;275: 17201-17210.
17. Freedman NJ, Lefkowitz RJ. Desensitization of G protein-coupled receptors. Recent Prog Horm Res. 1996;51:319-351; discussion 352-353.
18. Hamm HE. How activated receptors couple to G proteins. Proc Natl Acad Sci USA. 2001;98:4819-4821.
19. Terrillon S, Durroux T, Mouillac B, et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 2003;17:677-691.
20. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature. 2000;407:94-98.
21. AbdAlla S, Lother H, el Massiery A, et al. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med. 2001;7:1003-1009.
22. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316:1429-1435.
23. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
24. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
25. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
26. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
27. Gilbert S, Steinbrech DS, Landas SK, et al. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis. 1993;148:483-486.